Site prepares market for drug, educates patients on misdiagnosed disease

Site prepares market for drug, educates patients on misdiagnosed disease

Courtesy of ePharm5TM
Researching and reporting pharma business and marketing innovation
© 2006, HCPro, Inc.

For a subscription, please go to: http://www.epharmindepth.com

Biotech company Nutra Pharma is priming the market for a possible drug launch by sponsoring an educational Web site about the rare metabolic disorder Adrenomyeloneuropathy (AMN). The site, www.AMNhelp.com, aims to help people recognize AMN because it is often misdiagnosed as Multiple Sclerosis. AMNhelp.com provides information about symptoms, diagnosis, treatment research, and links to national, regional, and international support groups. However, the site has no interactivity or graphics. Currently, there is no approved treatment for AMN, and Nutra Pharma's subsidiary, ReceptoPharm, received Ethics Committee approval in the U.K. last year to begin a Phase IIb human trial for a treatment.